Skip to content

Registry-based randomized trial to determine the role of Oxygen in acute Pulmonary Embolism

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511959-18-01
Acronym
ROPE
Enrollment
4050
Registered
2024-05-27
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pulmonary Embolism

Brief summary

Composite of hemodynamic collapse or death from any cause within 30 days after enrollment.

Detailed description

Death from any cause within 30 days after enrollment, Hemodynamic collapse within 30 days after enrollment, Pulmonary embolism-related mortality within 30 days after enrollment, Length of hospital stay, Death from any cause within 90 days after enrollment, Serious adverse events within 30 days after enrollment, Major bleeding within 30 days after enrollment, Recurrent symptomatic venous thromboembolism within 30 days after enrollment

Interventions

DRUGOXYGEN

Sponsors

Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Composite of hemodynamic collapse or death from any cause within 30 days after enrollment.

Secondary

MeasureTime frame
Death from any cause within 30 days after enrollment, Hemodynamic collapse within 30 days after enrollment, Pulmonary embolism-related mortality within 30 days after enrollment, Length of hospital stay, Death from any cause within 90 days after enrollment, Serious adverse events within 30 days after enrollment, Major bleeding within 30 days after enrollment, Recurrent symptomatic venous thromboembolism within 30 days after enrollment

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026